Investors Catching Stocks HTG Molecular Diagnostics, Inc. (HTGM)

Cornelia Mascio
Marzo 28, 2017

The stock touched its 52-Week High on April 20, 2016 and 52-Week Low on Mar 24, 2017. We also noted a 2016-04-04 transaction in which HTGM President & CEO JOHNSON TIM B sold 4,914 shares at a stock price of $2.89, carrying a total value of $14200, after which, this insider's investment stands at 50,771 shares, with an overall financial value of $489940.

While taking a glance at financials, we can look at a number of key indicators.

The performance for week is 368.45% and the performance for quarter is at 397.42%. According to the Analysts, the Low Earnings estimate for the current quarter is $-0.07, while the High earnings estimate is $-0.01.Comparatively, EPS for the same quarter a year ago was $-0.09. These analysts have also projected a Low Estimate of $-0.77/share and a High Estimate of $-0.75/share.

Chesapeake Energy Corporation has 1 year price target of $7.3. The lowest price the stock reached on Friday was $22.76 and compares with the $12.05 52-week low. These price targets are a consensus analysis of 11 brokers. The current consensus recommendation provided by covering analysts is 1.50.

Delcath Systems, Inc. (NASDAQ:DCTH) closed down 0 points or 1.12% at $0.09 with 9.74 mln shares exchanging hands. (NASDAQ:HTGM), stock is trading $4.90 above the 52-week high. The stock stands almost $6.79 off versus the 52-week high of $6.88 and $0.01 above the 52-week low of $0.08.

The counter witnessed a trading volume of 113.21 million shares versus an average volume of 96.74 million shares during last trading session.

The company is estimating to achieve earnings per share (EPS) growth of 27.20% in this year and the earnings per share (EPS) growth expected to be 35.10% in the next year.

According to Finviz reported data, The SMA20 of the stock is at 282.81%, SMA50 is 357.67 percent, while SMA200 is 316.2%.

Indicating how profitable this stock is relative to its assets, the ROA value is observed at -92.10%.

At present the return on equity (ROE) stands at *TBA and the debt to equity stands at *TBA.

The company's ATR (Average True Range) is 1.16.

This recommendation lands on a scale between 1 and 5.

HTG Molecular Diagnostics, Inc.'s P/E ratio now stands at *TBA, while the P/S ratio is at 5.67 and the potential growth rate of earnings per share this year is at 27.20%. Analysts set a 12-month price target of $25.21 a share.

HTG Molecular Diagnostics, Inc. has a consensus buy rating from 2 Wall Street analysts, and the number of shares now sold short amount to at least 0% of shares outstanding. The stock stands almost 96.94% off versus the 52-week high and 704.17% away from the 52-week low.

For the upcoming quarter, initial predictions are anticipating that the company will post earnings of $-0.67 per share according to consensus of 2 analysts. The higher end of the revenue estimate is $2.44 Million and the lower end is $1.9 Million.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE